Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Journal of Bacteriology|July 26, 2021
Small Proteins; Big QuestionsTodd Gray, Gisela Storz, Kai PapenfortJournal of Cardiac Surgery|September 17, 2020
Occlusion following the deployment of MANTA VCD after TAVRMohammed F Hassan, Timothy Mixon, William Todd Gray, et al.Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|September 17, 2015
Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis CPaul Fredlund, Jan Hillson, Todd Gray, et al.The Lancet. Oncology|May 29, 2018
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b studyRashmi Murthy, Virginia F Borges, Alison Conlin, et al.European Urology|July 18, 2002
Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomesClaus G Roehrborn, John D McConnell, Brian Saltzman, et al.The New England Journal of Medicine|October 26, 2024
Atrasentan in Patients with IgA NephropathyHiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.JAMA Oncology|June 30, 2018
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical TrialVirginia F Borges, Cristiano Ferrario, Nathalie Aucoin, et al.Kidney International Reports|April 30, 2025
Corrigendum to "Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy" [Volume 10, Issue 1, January 2025, Pages 217-226]Hiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.Kidney International Reports|January 15, 2025
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA NephropathyHiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.Hepatology (Baltimore, Md.)|June 22, 2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionAndrew J Muir, Mitchell L Shiffman, Atif Zaman, et al.Pageof 2